Monash IVF Group Limited (ASX:MVF)
Australia · Delayed Price · Currency is AUD | Market Cap | 284.43M +5.8% |
| Revenue (ttm) | 269.39M -0.1% |
| Net Income | 15.16M |
| EPS | 0.04 |
| Shares Out | 389.63M |
| PE Ratio | 18.78 |
| Forward PE | 14.37 |
| Dividend | 0.05 (7.12%) |
| Ex-Dividend Date | Mar 4, 2026 |
| Volume | 286,967 |
| Average Volume | 1,053,796 |
| Open | 0.7350 |
| Previous Close | 0.7300 |
| Day's Range | 0.7300 - 0.7400 |
| 52-Week Range | 0.5370 - 0.8950 |
| Beta | 0.37 |
| RSI | 59.68 |
| Earnings Date | Aug 24, 2026 |
About Monash IVF Group
Monash IVF Group Limited engages in the provision of assisted reproductive and specialist women imaging services in Australia and Malaysia. It offers diagnostic obstetric, gynecological ultrasound, and fertility treatment services. It also provides tertiary level prenatal diagnostic, and IVF treatment services. Monash IVF Group Limited was incorporated in 2014 and is headquartered in Richmond, Australia. [Read more]
Financial Performance
Financial StatementsNews
Monash IVF Group Earnings Call Transcript: H1 2026
Underlying NPAT reached AUD 10.4 million at the upper end of guidance, despite revenue and market share declines in domestic IVF. International and genetics segments showed growth, and margin recovery is targeted through price increases and operational efficiencies into FY 2027.
Monash IVF Group Transcript: AGM 2025
Revenue and EBITDA grew in FY2025 despite sector headwinds and adverse incidents, with no final dividend declared. Board renewal and leadership transition are underway, and strategic investments continue, while competitive pressures and risk management remain key focus areas.
Monash IVF Group Earnings Call Transcript: H2 2025
Underlying NPAT for FY2025 was AUD 27.4 million, with revenue up 7% and EBITDA up 5.6%, despite market share declines and industry headwinds. FY2026 guidance is for lower NPAT due to a 10% drop in new patient registrations, but mid-single-digit growth is expected to resume from FY2027.
Monash IVF Group Earnings Call Transcript: H1 2025
Underlying NPAT grew 5.5% to AUD 15.8 million, with revenue up 12% and EBITDA margin steady at 25%. Market share gains, international growth, and cost optimization offset industry headwinds, supporting FY 2025 NPAT guidance of AUD 30–31 million.
Monash IVF Group Transcript: AGM 2024
Record financial growth was achieved in FY2024, with strong contributions from all business segments and significant international expansion. The class action settlement impacted results and board refreshment, while strategic focus remains on Southeast Asia and emerging growth drivers.
Monash IVF Group Earnings Call Transcript: H2 2024
Underlying NPAT reached AUD 29.9 million and revenue grew 19.4% year-over-year, despite a one-off class action settlement causing a net loss after tax. Market share, clinical outcomes, and international performance all improved, with strong growth expected in FY 2025.